Navigation Links
Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
Date:12/2/2008

VANCOUVER, Dec. 2 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced the initiation of a clinical trial of the Company's RAMP(R) test to detect Respiratory Syncytial Virus (RSV). Prospective data from the clinical study is expected to be used to support a submission to the U.S. Food and Drug Administration (FDA) and other regulatory jurisdictions for market clearance of the 3M Rapid Detection RSV test for clinical use. The study is designed to demonstrate the performance characteristics of the RSV test versus standard laboratory culture and Direct Fluorescence Staining Assay (DFSA) for RSV using multiple sample types. The study is a multi-centre prospective clinical study to be conducted in North America at approximately eight clinical sites.

"We are excited to commence this clinical trial, which is the second clinical indication in infectious diseases developed for 3M Health Care," said S. Wayne Kay, Chief Executive Officer. "RSV is a very common disease that affects most children in their first two years of life. RSV is also common in the elderly and is often confused with influenza. There remains a significant clinical need for a rapid test that provides high clinical sensitivity for RSV compared to viral culture or DFSA."

The successful development of this test would allow physicians to quickly diagnose the presence or absence of RSV virus and optimize the clinical management of the RSV positive patient. A highly sensitive and rapid RSV test would allow more effective management of large RSV outbreaks and reduce the amount of unnecessary antibiotic administrations.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in
'/>"/>

SOURCE Response Biomedical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy
2. FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
3. Bayer HealthCare Donates Hundreds of Food Items to Community Food Bank of New Jersey in Response to Governors Plea to Help the States Population in Need
4. Zimbabwean Health Workers Call For Crisis Response
5. TV News Story on Canine Cancer Generates Dog Lover Response - No. 1 Health Issue for Americas 40 Million Dog-Owning Households
6. iMedExchange Responses to Financial Crisis
7. Response rates to antidepressants differ among English- and Spanish-speaking Hispanics
8. Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
9. Response Biomedical Closes $5.1 Million Financing
10. A useful imaging modality for monitoring treatment response to hepatocellular carcinoma
11. Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)... Dr. David Kim of the Live Life Again C... Dallas , is one of a growing number of physicians...rking sites to connect with individuals who are in...t morbid obesity. Dr. Kim is utilizing Facebook to...ut his practice with the community. , ...
(Date:11/25/2009)...CITY,Mo.,Nov.25/PRNewswire/--TheBartleHallConventi...icalcliniconDec.9-10,whenKansasCityhoststhelatesti..., "Thisfreecliniceventhasthepotentialtobethebigg...ustoneandbeheldonweekdaysinsteadofoveraweekend,"Sh...ClinicandpresidentoftheNationalAssociationofFreeCl...
(Date:11/25/2009)...SPRING,Md.,Nov.25/PRNewswire-USNewswire/--Anarticl...rugEvaluationandResearch,titled"ADifficultBalance-...ov.26,2009issueofTheNewEnglandJournalofMedicine. ,...090824/FDALOGO ) ,, Inthearticle,Woodcockdiscus...dicationforthosewhoneeditandmanagingtherisksposedb...
(Date:11/25/2009)...have found evidence of a statistically significant...tients whose estrogen receptor (ER)-positive tumor...at serine-118 (ER-alpha S118-P), according to a br...the Journal of the National Cancer Institute . ,...tant to tamoxifen. Preclinical studies have shown ...
(Date:11/25/2009)... Evaluation and treatment clinics to re...odstock (Vocus) November 25, 2009 -- Centegra Heal...es and H1N1 vaccine shots at four Centegra Primary...ment of vaccine has arrived. The clinics are at CP...Henry and will be open as follows: ,   ...
Breaking Medicine News(10 mins):Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...Currently lie detection methods use heart activity... quite accurately for lie detection reports the on...n scientist Pankaj Pasricha at the University of T...own - literally. It has its own well-developed ner...
... The government of India has today assured that th...a) in the country // The government has set...se eye on the on the domestic poultry population a...ose watch on the situation. Extensive surveillance...
... A new study indicates that there maybe gender dif...cer and women who smoke and drink maybe at higher...r Anna L. Zisman, M.D. of Evanston Northwestern He...hol use are well-established risk factors for colo...
...tudy was conducted to investigate the association ... density (BMD), and cardiovascular risk factors. T...her bone mineral // density than the controls, and...diabetics have bone mass alterations and may have ...
...-mediated bone marrow injury is an early or predis...d persistent hematopoietic disease, according to r...r 23 in the journal Leukemia Research. My...s, clonal evolution and a tendency to progress on ...
...ers have been used widely in the treatment of hype...rugs in hypertension guidelines. Moreover, after m...ilure, treatment // with beta blockers prevents re...hypertension. A recent study, published in t...
Other Medicine News:Health News:Women More Prone To Risk of Colorectal Cancer from Tobacco 2Health News:Diabetic Type II Women Have Elevated Bone Density Mass 2Health News:Evidence against use of Beta blockers as first choice in the treatment of primary hypertension 2
(Date:11/25/2009)...ire/--Reportlinker.comannouncesthatanewmarketresea...nagement-GlobalTrends ,, http://www.reportli...html ,, Widespreadavailabilityofgenericdrugs,e...rugshaveacceleratedthepaceofgrowthinthepainmanagem...recontinuetoshapedemandforservices,drugsanddevices...
(Date:11/25/2009)...v.25/PRNewswire/-- ChemoCentryx,Inc.,announcedtod...CT-1(theProspectiveRandomizedOralTherapyEvaluation...npatientswithmoderate-to-severeCrohn,sdiseasedemon...rabilityprofile.Thestudydemonstratedevidenceofclin...edasa70-pointdecreaseintheCrohn,sDiseaseActivityIn...
(Date:11/24/2009)...Newswire-FirstCall/--QuestDiagnosticsIncorporated(...esting,informationandservices,announcedthatitissch...ConferenceinNewYorkCity.Thepresentationisscheduled...,, Duringtheconference,thecompanywillreaffirmit...tingincometoexceed18%ofrevenues,anddilutedearnings...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2LightLab 28R 29 Imaging Showcases Advanced OCT System Technology at TCT 2009 57670 1LightLab 28R 29 Imaging Showcases Advanced OCT System Technology at TCT 2009 57670 2LightLab 28R 29 Imaging Showcases Advanced OCT System Technology at TCT 2009 57670 3Accera Inc to Present at UBS Global Life Sciences Conference 57667 1Accera Inc to Present at UBS Global Life Sciences Conference 57667 2Ulcer Preventative May Raise Pneumonia Risks 57664 1Ulcer Preventative May Raise Pneumonia Risks 57664 2
...SINESS WIRE)--Jun 13, 2007 - EPIX,Pharmaceuticals,...m,its Phase 3 trial of PRX-00023, a novel long-act...ntation at the 47th Annual New,Clinical Drug Evalu... The meeting is sponsored by the National Institut...Psychopharmacology., The presentation highlighted ...
...-(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite,BioPharm...he Tel,Aviv Stock Exchange Exchange, proceeds with...in addition to CF101, which is currently,in clinic...s. This,weekend Can-Fite will present at the EUALR...ivo study results showing effective,anti-inflammat...
Other Medicine Technology:EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2
HemoCue 201 DM System, Glucose
Triage® C. difficile Panel
Bartels® C. Difficile Toxin A Antigen EIA with Controls
... Toxin A C. difficile Rapid Toxin A Test gives you...minutes. When it might be C. difficile, you can't ...nly a few tests a day or sends out its suspected C...C. difficile Rapid Toxin A Test will cut costs and...
Medicine Products: